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ABSTRACT Osteoarthritis (OA) is the most common
form of arthritis. It is characterized by cartilage de-
struction and bone remodeling, mediated in part by
synovial fibroblasts (SFs). Given the functional signifi-
cance of cadherins in these cells, we aimed at determin-
ing the role of genetic variants of N-cadherin (CDH2) in
OA of the knee and hip. Six single-nucleotide polymor-
phisms in the genomic region of the CDH2 gene were
genotyped in 312 patients with OA and 259 healthy
control subjects. Gene expression of CDH2 was ana-
lyzed by qRT-PCR. Liquid chromatography-mass spec-
trometry was used to identify a transcription factor
isolated by DNA pulldown. Its potential for binding to
gene variants was examined by electrophoretic mobility
shift assay, enzyme-linked immunosorbent assay, and
chromatin immunoprecipitation. Genetic analysis iden-
tified a polymorphism located in the CDH2 promoter
region to be associated with risk of OA. The minor
allele of rs11564299 had a protective effect against OA.
Compared to carriers of the major allele, carriers of the
minor allele of rs11564299 displayed increased N-
cadherin levels in SFs. Based on in silico analysis, the
minor allele was predicted to generate a novel tran-
scription factor binding site, Direct-binding assays and
mass spectrometric analysis identified hnRNP K as
binding selectively to the minor allele. In summary, a
CDH2 promoter polymorphism influences the risk of
OA, and hnRNP K was found to be involved in the
regulation of elevated N-cadherin expression in pa-
tients with OA carrying the minor allele of rs11564299.—
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Osteoarthritis (OA) is the most common form of
arthritis. Cartilage destruction and bone remodeling
characterize this painful and disabling disease. OA is a
complex disease, and both environmental and genetic
factors play a role in disease susceptibility. Several
genetic loci with genome-wide significance have been
identified for hip and knee OA (1–3). Three important
points came up in these genetic studies: first, the effects
of the common variants are low to moderate; second,
differences between European and Asian study samples
have been reported; and third, joint-specific genetic
effects are involved (4, 5). Despite the replication of
genetic risk variants, the molecular pathogenesis is still
poorly understood. However, there is growing evidence
that fibroblasts of the synovial membrane from OA
patients [OA synovial fibroblasts (OASFs)] play an
important role. It has been shown that activated OASFs
are capable of migrating into and destroying the carti-
lage (6), thereby contributing to disease progression
and severity.
Cadherins are a family of structurally related, calcium-
dependent cell–cell adhesion proteins that play impor-
tant roles in cell adhesion and migration in processes
ranging from embryogenesis to cancer metastasis (7).
Human in vitro and murine in vivo studies have estab-
lished a critical role of cadherin 11 in the development
and architecture of the synovium and in modulating
the capacity of synovial fibroblasts (SFs) to produce
cytokines, chemokines, and other inflammatory factors
(8, 9). Less is known about the role of N-cadherin,
which is encoded by the CDH2 gene (10), has been
found to be coexpressed with cadherin 11 on murine
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SFs (11), and has been reported to suppress or pro-
mote invasion in different kinds of cancer. For exam-
ple, the loss of N-cadherin has been reported to lead to
reduced cell–cell adhesion in osteosarcoma. There-
fore, the absence of N-cadherin promotes metastasis in
these cells (12). In contrast, it has been shown that
N-cadherin expression in, for example, melanoma cells
or pancreatic cancer cells leads to increased metastasis;
therefore, overexpression promotes migration (13–15).
Here, we describe changes of N-cadherin expression at
the mRNA level in OASFs in association with a single-
nucleotide polymorphism (SNP) in the N-cadherin
promoter. Bringing together both genetic association
studies and functional data could lead to the identifi-
cation of novel pathways of OA onset and progression.
MATERIALS AND METHODS
Study population
A total of 571 Slovak individuals (127 males, 444 females)
were included in the study: 312 patients with OA (60 males,
252 females) and 259 healthy control subjects (67 males, 192
females). OA disease status of the knee, hand, and hip were
clinically and radiographically ascertained. The control sub-
jects were selected by clinical exclusion of arthritic or degen-
erative symptoms. Further phenotype details are shown in
Table 1. Our study case patients and control subjects did not
differ in gender, but the latter were significantly younger
(P0.001).
Subjects’ written consent was obtained according to the
current Declaration of Helsinki. The study was approved by
the ethics committees of the Slovakia National Institute of
Rheumatic Diseases (Piestany, Slovakia) and the University of
Regensburg (Regensburg, Germany).
Marker selection and genotyping
SNPs in the CDH2 genomic region (NM_001792.3) on chro-
mosome 18 were selected to cover the gene without redun-
dancy with respect to linkage disequilibrium (LD) structure:
1 SNP at the distal promoter (rs11083271), 1 SNP at the
proximal promoter (rs11564299), 1 SNP in intron 2 (rs11564392),
and 1 SNP at the 3= end of the gene (rs2871593). In addition,
rs4131805, located 302 kb upstream of the CDH2 5= end, was
included because of a reported association with bone density
and geometry (16). Therefore, 542 kb of the genomic region
was analyzed with1 SNP in each distinct LD block (Fig. 1A).
After a first round of association testing, SNP rs11083255 was
analyzed as an additional marker in the CDH2 promoter
region. For information on all SNP markers analyzed, see
Table 2.
Genomic DNA was isolated from whole-blood specimens
with the PureGene DNA Blood Kit (Qiagen, Hilden, Ger-
many). DNA samples were genotyped with 5= exonuclease
TaqMan technology (Life Technologies; Applied Biosystems,
Foster City, CA, USA), according to the manufacturer’s
instructions. In brief, for each genotyping experiment, 10 ng
DNA was used in a total volume of 5 l containing 1
TaqMan Genotyping Master Mix. Polymerase chain reaction
(PCR) and post-PCR end point plate reading was performed
on an Applied Biosystems 7900HT Real-Time PCR System.
Sequence Detection System 2.3 software (Life Technologies)
was used to assign genotypes applying the allelic discrimina-
tion test. Case and control DNA were genotyped together on
the same plates with duplicates of samples (10%) to assess
intraplate and interplate genotype quality. No genotyping
discrepancies were detected. Assignment of genotypes was
performed by a person without knowledge of the proband’s
affection status.
Cell culture, RNA extraction, and real-time quantitative
reverse transcription PCR (qRT-PCR) analysis
Synovial tissue specimens were obtained from patients with
OA immediately after the knee joint capsule was opened (17).
Synovial cells from patients with OA were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Sigma-Aldrich, Munich,
Germany), 10% fetal calf serum (FCS; PAN Biotech, Aiden-
bach, Germany), and penicillin and streptomycin (P/S)
(PAA, Piscataway, NJ, USA). The same medium was used to
grow the cell lines HSE (immortalized rheumatoid SFs) and
K4Im (immortalized normal SFs), which were kindly pro-
vided by Prof. W. K. Aicher (University of Tübingen, Tübin-
gen, Germany). Total cellular RNA was isolated from cultured
cells with the RNeasy kit (Qiagen), and cDNAs were gener-
ated by reverse transcription. In parallel, genomic DNA from
cultured cells for genotyping was isolated with the QIAamp
DNA Mini Kit (Qiagen). qRT-PCR was performed with SYBR
Green master mix (Qiagen), with the primer pair 5=-TGGAT-
GAAGATGGCATGG-3= and 5=-AGGTGGCCACTGTGCT-
TAC-3=, targeting exon A to exon B of CDH2. Relative gene
expression was normalized to -actin mRNA levels by using
TABLE 1. Characteristics of study population for association analyses
Variable OA case patients OA-free control subjects
n 312 259
Gender, [% female (n)] 80.8 (252) 74.1 (192)
Age at inclusion [yr (range)] 57.9  13.5 (21–83) 39.3  15.1 (18–78)***
Age of onset [yr (range)] 50.8  12.8 (14–82) NA
Isolated knee OA (n) 68 –
Isolated hip OA (n) 74 –
Isolated hand OA (n) 19 –
Combined knee and hip OA (n) 79 –
Combined knee and hand OA (n) 7 –
Combined hip and hand OA (n) 5 –
Combined knee, hip and hand OA (n) 5 –
Not classified (n) 55 –
Values are means  sd. NA, not applicable. ***P  0.001.
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the comparative cycle threshold (Ct) method. The Mel-Im cell
line was used as a calibrator sample.
Preparation of nuclear extracts
Nuclear extracts from OASFs were prepared by using the
method of Dignam et al. (18).
Enzyme-linked immunoabsorbent assay (ELISA)
For quantitative measurement of the binding capacity of
transcription factors, a sandwich ELISA was established based
on a previously published protocol (19). 5=-Biotinylated (Btn)
forward oligonucleotides that contained either variant A [5=-(Btn)-
TATTCCTTCTTGTAA-3=] or variant G of rs11564299 [5=-
(Btn)TATTCCTCCTTGTAA-3=] were annealed overnight to
reverse complementary, nonbiotinylated oligonucleotides
(5=-TTACAAGAAGGAATA-3= and 5=-TTACAAGGAGGAATA-
3=, respectively) and then were bound onto streptavidin-
coated plates. After 3 washes of the plates with PBS, nonspe-
cific binding was blocked with incubation buffer (MIA ELISA;
Roche Applied Sciences, Mannheim, Germany) for 1 h.
Nuclear proteins from HSE cells, 6 g in 150 l of incubation
buffer, were allowed to bind to the oligonucleotides for 1 h.
Figure 1. A) Schematic representation of the
600-kb CDH2 genomic region from the University
of California at Santa Cruz (UCSC) Genome
Browser (http://genome.ucsc.edu/). a) Position
on chromosome 18 according to human genome
build 18 from 23,750 to 24,350 kb. b) SNP markers
from the text with their relative positions (vertical
lines) in or near CDH2. c) Structure of the CDH2
gene, with vertical lines and boxes depicting ex-
ons. Horizontal lines represent introns with arrows
showing the orientation of the gene from right to
left. d) LD plot from CEU samples of HapMap
phase II release 22 with pairwise r2 values. Red
denotes perfect LD with r21, and decreasing
r2values are shown in lighter shades (white repre-
sents r20). B) Box-and-whisker plots of CDH2
mRNA expression for rs11564299 genotypes. Boxes represent the 25th to 75th percentiles; horizontal lines
within boxes represent median values. Whiskers show the 5th and 95th percentiles.
TABLE 2. SNP markers
SNP TaqMan assay Position on chromosome 18a Localization
Alleles
Call ratebMajor Minor
rs2871593 C_15841206_20 23,771,322 3= Intergenic A G 0.95
rs11564392 C_30810483_10 23,933,730 Intron 2 T C 0.95
rs11083255 C_27837839_10 24,013,162 Promoter T C 0.97
rs11564299 C_30810437_20 24,014,026 Promoter A G 0.95
rs11083271 C_417876_10 24,180,057 5= Intergenic C T 0.95
rs4131805 C_26772835_20 24,313,110 5= Intergenic T C 0.95
aNational Center for Biotechnology Information (NCBI; Bethesda, MD, USA) build 36.3 (human genome build 18).bBased on n  571
samples.
685N-CADHERIN GENE VARIANTS AND RISK OF OA
For displacement analysis, double-stranded oligonucleotides
(ds-oligonucleotides) without the biotin label were incubated
with the nuclear extracts for 10 min before incubation on the
plate. The plates were then washed 3 times with incubation
buffer, followed by incubation with a specific antibody against
ETS-1 (1:500; Novocastra; Leica Biosystems, Wetzlar, Ger-
many) or heterogeneous nuclear ribonucleoprotein K (hn-
RNP K; 1:500; Acris Antibodies, San Diego, CA, USA) for 1 h.
After 3 washes with incubation buffer, a secondary antibody,
anti-mouse or anti-rabbit (1:1000; Cell Signaling Technology,
Danvers, MA, USA) conjugated with horseradish peroxidase,
was added for 30 min. The binding was measured by using
ABTS solution (Roche Applied Sciences).
Pulldown assay
5=-Biotinylated forward oligonucleotides containing either vari-
ant A or G of rs11564299 were annealed overnight to their
respective complementary, nonbiotinylated strands [5=-
(Btn)TATTCCTTCTTGTAA-3= and 5=-TTACAAGAAGGAATA-
3= ; and 5= -(Btn)TATTCCTCCTTGTAA-3= and 5= -
TTACAAGGAGGAATA-3=]. Streptavidin beads (GE Healthcare
Europe GmbH, Freiburg, Germany) were washed with 1 ml of
ice-cold PBS. Then, the beads were incubated with the annealed
5=-biotinylated oligonucleotides overnight. Nuclear extracts
from the HSE cells were precleared by incubation with strepta-
vidin beads overnight. On the next day, the precleared lysate was
incubated with the oligonucleotides bound to streptavidin beads
for 4 h. The samples were analyzed by SDS-PAGE, followed by
silver staining. The bands selectively occurring in the samples of
the minor variant of rs11564299 were cut out and analyzed by
mass spectrometry (MS).
MS
Respective bands were excised and washed according to
Shevchenko et al. (20) with slight modifications. Briefly, gel
pieces were washed 3 times alternately with 50 l of 50 and 25
mM NH4HCO3 in 50% acetonitrile. Subsequently, the gel
slices were dried in a vacuum centrifuge. Trypsin solution (5
l; 12.5 ng/l in 50 mM NH4HCO3) was added to each gel
piece and incubated at 37°C overnight for in-gel digestion.
The obtained peptides were eluted with 20 l of 5% formic
acid and subjected to nano-LC-MS/MS-analysis on an Ulti-
mate 3000 nano-HPLC system (Dionex GmbH, Idstein, Ger-
many). The samples were preconcentrated on a 300 m i.d.,
5 mm C18-PepMap precolumn (5 m, 300 Å; Thermo Fisher
Scientific, Idstein, Germany), with 0.1% formic acid and a
flow rate of 40 l/min. The peptides were then separated on
a 75 m i.d., 15 cm, C18-PepMap-column (flow rate 300
nl/min; Thermo Fisher Scientific), with a 1 h binary gradient
from 4 to 40% of solvent B (solvent A: 0.1% formic acid;
solvent B: 0.1% formic acid in acetonitrile). The nano-HPLC
was directly coupled to a quadrupole time-of-flight (QTOF)
mass spectrometer (QStar XL; AB Sciex, Darmstadt, Ger-
many) acquiring 1 full MS and 2 MS/MS spectra of the most
intense ions in the respective full-MS scan, repeatedly. The
MS/MS spectra were searched against the Uniprot database
with the Mascot Daemon and the Mascot algorithm (version
2.2; Matrix Science Ltd., London, UK), with trypsin used as
the protease with a maximum of 1 missed cleavage site,
oxidation of methionine as a variable modification, and 0.2
Da tolerance for MS and MS/MS signals. Only proteins with
2 significantly scored peptide spectra that passed manual
inspection were considered to be positive identifications.
Electrophoretic mobility shift assay (EMSA)
Two double-stranded oligomeric binding sites with either
variant A (5=-TACAAGAAGGAA-3=) or variant G (5=- TA-
CAAGGAGGAA-3=) of rs11564299 were generated. The ds-
oligonucleotides were end labeled with T4 polynucleotide
kinase (Roche Applied Sciences) and [32P]ATP[P] (Am-
ersham-GE Healthcare, Munich, Germany). Band shifts
were performed by incubating 5 g recombinant hnRNP K
(Cusabio Biotech, Wuhan, China) in 5 mobility shift
buffer [1 g of poly(dI-dC)(dI-dC), 40% glycerol, 25 mM
MgCl2, 1 mM EDTA, 25 mM dithiothreitol, 250 mM KCl,
and 25 mM HEPES/KOH, pH 7.9) with the DNA probe for
10 min before separation on a 6% nondenaturing poly-
acrylamide gel. DNA-protein complexes were resolved on a
nondenaturing polyacrylamide gel at 250 V, 50 mA, and
100 W for 1.5 h (21).
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described by the manufacturer
(ChIP-IT Enzymatic; Active Motif, La Hulpe, Belgium). Spe-
cific antibodies against hnRNP K (Sigma-Aldrich), ETS-1
(Novocastra), polymerase II (Active Motif), and IgG (Active
Motif) were used. For qRT-PCR, primers spanning the region
around rs11564299 were designed (hCDH2 rs11564299 for-
ward, 5=-CTTCTTGTAATCAGAGGCC-3=, and hCDH2 rs11564299
reverse, 5=- ATTGTTTTAGCATCTTGCC-3=). For quantifica-
tion of the positive control, commercially available GAPDH
primers (Active Motif) were used.
Statistical analyses and bioinformatics tools
Differences between dichotomous traits were calculated by 2
test. Differences in continuous variables between groups were
calculated with a 2-tailed t test for normally distributed values
or with the nonparametric Wilcoxon rank sum test for
variables that failed normal distribution, as determined by the
Shapiro-Wilk test. Expression data between the 3 genotype
groups were compared by Kruskal-Wallis test. Association
analysis was carried out in a logistic regression model with
gender as a covariate. When age of onset was included as a
covariate, for the controls age at inclusion was used. Preva-
lence ORs with their 95% CIs were reported. Values of P 
0.05 were considered significant. To determine whether the
genotypes of case patients and control subjects of all SNPs
deviated from Hardy-Weinberg equilibrium (HWE), actual
and predicted genotype counts of both groups were com-
pared by an exact test (22). Association analyses were per-
formed with PLINK 1.07 (23), and the statistical software
package JMP 7.0.2 (SAS Institute, Inc., Cary, NC, USA) was
used for other analyses. For LD testing, HaploView 4.2 was
used (24) with HapMap phase II data from releases 22, 24,
and 27 (25). MatInspector 8.04, and SNPInspector 2.2 (Geno-
matix Software GmbH, Munich, Germany) were used to
analyze the potential functional effects of SNPs on transcrip-
tion factor binding sites.
RESULTS
Testing for genetic association
All genotyped markers fulfilled our criteria of a 95%
call rate and showed no deviation from HWE (Table 3).
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The 5 SNPs genotyped initially were not in tight LD
(maximum r20.03 in the entire study sample of 571
persons). There was a significant association (P1.5
10	3) between rs11564299 and risk of OA in logistic
regression analysis after adjustment for gender. Signif-
icance decreased to P  5.0  10	3 after additional
adjustment for age of recruitment (Table 3). In the
fully adjusted model, SNP rs11083271 was nominally
associated with OA risk (P0.02; Table 3). Because
rs11564299 is localized in the promoter region 2583 bp
upstream of the CDH2 5= end, we searched the HapMap
data for polymorphisms closer to the CDH2 transcrip-
tion start site. The SNP marker rs11083255 is localized
1719 bp upstream of CDH2 and was included in a second
round of genotyping. Both rs11564299 and rs11083255
were in weak LD in our study sample (r20.215). A
significant association between rs11083255 and OA risk
was detected (P1.210	3 for logistic regression ad-
justed for gender; P1.110	2 for logistic regression
adjusted for gender and age at recruitment; Table 3).
The effect direction for both SNPs was the same, with a
protective effect of the minor allele (Table 3). Taking
multiple testing with a total of 6 markers into account,
only rs11564299 showed significant association with OA
risk in our study (P5.010	36 tests0.03).
Conditional logistic regression analysis with each
nominally associated SNP showed that rs11083255 and
rs11564299 were not fully independently associated
with OA risk (P0.040, OR0.69 for rs11564299, after
adjustment for rs11083255; P0.166, OR0.61 for
rs11083255, after adjustment for rs11564299)—that
is, loss of significance of 1 order of magnitude was
observed. As assumed by LD, rs11083271 did not fully
explain the association results for rs11564299 (P0.018,
OR0.67) and rs11083255 (P0.020, OR0.46).
Because our study sample included different pheno-
types of OA (Table 3), we performed separate analyses
on samples of knee OA and hip OA. A comparison of
68 patients with isolated knee OA with 259 control
subjects showed that 3 markers from the combined
analysis (rs11083255, rs11564299, and rs11083271) re-
mained significantly associated (logistic regression us-
ing gender and age at inclusion as covariates; P0.016,
P0.036, and P0.042, respectively). For hip OA (n
74 cases), no association was detected (P0.639, P
0.071, and P0.887, respectively).
Expression analysis
A total of 29 synovial cell specimens were available from
patients with knee OA. Comparison of CDH2 mRNA
expression levels between heterozygotes (n3) and
homozygotes (n26) for the major allele of rs11083255
did not reach the significance level (P0.43). The 3
genotypes of rs11564299 were strongly associated with
CDH2 mRNA expression (P0.0086). Comparison be-
tween rs11564299 heterozygotes (n9) and homozy-
gotes (n19) for the major allele yielded P  0.0073
(Fig. 1B). For both SNPs, the mean expression of CDH2
was higher in carriers of the minor alleles (e.g., rs11564299:
heterozygotes, mean1.040.94; homozygotes, mean
0.260.33).
TABLE 3. Results of an SNP association analysis in an OA case–control sample
Association
SNP
rs2871593 rs11564392 rs11083255 rs11564299 rs11083271 rs4131805
OA case
patient
genotypes
11 275 290 286 200 145 189
12 35 22 22 99 134 104
22 2 0 0 12 31 18
MAF 0.0625 0.0353 0.0357 0.1977 0.3161 0.2251
P, HWE 0.337 1 1 1 1 0.515
OA control
subject
genotypes
11 225 246 209 140 140 146
12 31 13 36 92 98 102
22 3 0 3 27 20 11
MAF 0.0714 0.0251 0.0847 0.2819 0.2674 0.2394
P, HWE 0.127 1 0.396 0.064 0.634 0.233
Results
Pa 0.5024 0.3597 0.0012 0.0015 0.0644 0.5843
Pb 0.8894 0.7640 0.0107 0.0050 0.0221 0.9739
OR for minor
allele [OR
(95% CI)]
1.04 (0.61–1.76) 1.14 (0.49–2.62) 0.48 (0.23–0.83) 0.63 (0.46–0.87) 1.44 (1.05–1.96) 0.99 (0.71–1.39)
Numbers of the genotypes (i.e., 11, 12, 22) are according to the alleles in Table 1. MAF, minor allele frequency. aLogistic regression adjusted
for sex.bLogistic regression adjusted for age at inclusion and sex.
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In silico data
That the G allele of rs11564299 was associated with
elevated CDH2 mRNA levels in OASF led to the hypoth-
esis that this allele may generate a novel transcription
factor binding site. In silico analysis with Genomatix
(Genomatix Software GmbH) predicted the loss of a
TEF (26) binding site and a gain in sites for ETS-like
transcription factors (27) and ZNF35 (28).
Analysis of a potential transcription factor binding
site
A quantitative ELISA with ds-oligonucleotides contain-
ing either variant A or G of rs11564299 as bait was
established to verify the predicted ETS-like binding site.
After incubation with nuclear proteins and detection
with a specific ETS-1 antibody and peroxidase-labeled
secondary antibodies, no differences in binding effi-
ciency to one of the variants were observed (Fig. 2A).
Therefore, ETS-1 was excluded as a transcription factor
binding selectively to the minor allele of rs11564299.
Subsequently, a pulldown assay was performed for
identification of the transcription factor responsible for
the higher CDH2 mRNA levels observed with the minor
rs11564299 allele. The pulldown was performed with
nuclear extracts of the cell line HSE, which had tested
heterozygous for rs11564299, by using the specific
oligonucleotides for alleles A and G of rs11564299.
Pulled down proteins were separated on an acrylamide
gel and stained silver, followed by excision, tryptic
digestion, and MS analysis of those protein bands that
had been pulled down selectively with ds-oligonucleo-
tides containing variant G (Fig. 2B). This method
revealed hnRNP K as a potential binding protein.
Expression of hnRNP K in early (P3) and late (P8)
passages of OASFs was determined by qRT-PCR, and no
significant differences were observed between the dif-
ferent groups (Fig. 2C). For analysis of differential
binding of hnRNP K to the minor allele (G) compared
to the major allele (A) of rs11564299, a quantitative
ELISA with a specific hnRNP K antibody was estab-
lished. The ELISA showed that hnRNP K bound only to
ds-oligonucleotides containing variant G, but not to
those containing variant A (Fig. 3A). The binding was
inhibited by preincubation with ds-oligonucleotides
containing variant G but not variant A (Fig. 3A). As
shown before, performing the ELISA with an ETS-1
antibody revealed no differential binding of ETS-1 to
ds-oligonucleotides containing either variant of the
SNP rs11564299 (Fig. 2A). As a negative control, a
setting with the forward biotinylated ssDNA oligonucle-
otides was performed, but did not show any binding of
hnRNP K to the ssDNA (data not shown). EMSAs of
similar oligonucleotides yielded the same results. A
shift was observed only for probes carrying variant G
after incubation with recombinant hnRNP K (Fig. 3B).
This result showed that hnRNP K bound exclusively to
the minor allele of rs11564299, indicating that hnRNP
K may be responsible for elevated CDH2 mRNA expres-
sion. To further elucidate the binding of hnRNP K to
the minor variant of rs11564299, a ChIP assay was
performed. Antibodies against ETS-1 (positive control
1), pol II (positive control 2), and IgG (negative
control) were used in addition to the anti-hnRNP K
Figure 2. A) ELISA, performed with an ETS-1
antibody, did not show preferential binding to
one of the 2 alleles of rs11564299. Here, com-
petition was possible with variants A and G. B)
Silver-stained acrylamide gel of a pulldown assay
using oligonucleotides containing either allele
A or G of rs11564299. A band, showing only the
pulldown with variant G, was analyzed by MS
and revealed hnRNP K as a potential transcrip-
tion factor binding to the CDH2 promoter with
the minor allele G. C) mRNA expression of
hnRNP K was not altered during cell culture
cultivation of OASFs.
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antibody. The ChIP assay was performed with HSE
cells, which are heterozygous for rs11564299, and
K4Im, a cell line of immortalized SFs that are homozy-
gous for the major allele of rs11564299. hnRNP K
bound only to chromatin in HSE cells, whereas no
binding was observed when the homozygous wild-type
K4Im cells were tested (Fig. 3C). These findings con-
firmed that hnRNP K bound exclusively to the N-
cadherin promoter in the presence of the minor allele
of rs11564299, therefore making hnRNP K a candidate
for inducing the elevated levels of N-cadherin.
DISCUSSION
Genetic association studies have shown that SNPs con-
tribute significantly to the susceptibility and severity of
many diseases (29). Also, associations of genetic vari-
ants with OA onset and progression have been pub-
lished (2, 30). As shown before, SNPs in the promoter
region of a gene can influence disease susceptibility
(31, 32). Our results indicate that CDH2 SNP
rs11564299 influences susceptibility to OA prevalence,
as the minor G allele is more common among the
control population than the OA population. We found
that the allelic state of rs11564299, which is located
2583 bp upstream of the CDH2 transcription start site,
significantly affected mRNA expression levels of CDH2
in SFs, with the AG heterozygotes (HSE cells) express-
ing significantly more CDH2 than the AA homozygotes
(K4Im cells). This result indicates stronger activity of
the CDH2 promoter in patients carrying the minor
allele, probably caused by an allele-specific transcrip-
tion factor binding site. However, none of the transcrip-
tion factors predicted in silico to bind to the variant
promoter sequence showed differential binding to the
minor allele of rs11564299. Rather, MS analysis identi-
fied hnRNP K as a factor that bound exclusively to the
G allele of rs11564299 and not to the A allele. hnRNP
K is one of the major pre-mRNA binding proteins. It
has also been described to bind dsDNA and to act as a
transcription factor (33). Binding of hnRNP K was
confirmed by a specific ELISA and ChIP. Thus, hnRNP
K appears to contribute to the increased N-cadherin
expression levels in SFs carrying the G allele of
rs11564299. As N-cadherin is a core component of
adherens junctions, the increased levels of it may affect
cell–cell contacts, tissue architecture, and cell motility
(34, 35). It has been described before that N-cadherin
levels are critical for cell invasion and that N-cadherin
re-expression in glioma cells and in human arterial
smooth muscle cells leads to less migration (36, 37).
Therefore, higher N-cadherin levels in SFs may lead to
a decreased migratory potential of the cells. As shown
by Schubert et al., (6) migration of SF into cartilage
leads to the degradation of the extracellular matrix and
cartilage loss. Thus, inhibition of migration by en-
hanced cell–cell contact may prevent or reduce carti-
lage destruction. All evidence combined, our study
implicates for the first time CDH2 encoding N-cadherin
as a susceptibility gene for OA, especially of the knee.
Some limitations of our study should be discussed. First,
we had no replication study for the genetic association
data, and therefore our finding of rs11564299 as a risk
Figure 3. A) For quantitative measurement of the binding capacity of hnRNP K,
an ELISA was established with specific oligonucleotides containing variant A or
G. A clear binding to variant G was observed, whereas no binding K to variant A
was measured. Binding was repressed only in competition experiments with
variant G oligonucleotides, not with variant A. B) EMSAs with the variant A or
G probes showed binding only to variant G. C) Specific binding of hnRNP K to
variant G was confirmed by ChIP. In heterozygous HSE cells, binding was
observed, whereas in K4Im cells, which are homozygous for variant A, only
binding to ETS-1 was detected. Top panel: HSE. Bottom panel: K4Im. Lane 1,
input; lane 2, IgG antibody; lane 3, Pol II antibody; lane 4, hnRNP K antibody;
lane 5, ETS-1 antibody; lane 6, H2O control. (Differential binding of ETS-1 in
the control setting is due to base pair changes in the GAPDH promoter region
of K4Im, which resulted in an ETS-1 binding site; data not shown.)
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factor for OA susceptibility could be a false positive.
However, the apparent link between rs11564299 allelic
state and CDH2 mRNA expression lends functional
support to this hypothesis. Second, the effect size of the
rs11564299 minor allele on OA risk is small (OR0.63,
i.e., 
1.6 times increased risk in carriers of the major
allele). However, it has become obvious that common
variants are often associated with OR 1.5 (38). Third,
because the control subjects were selected by clinical
exclusion of arthritic or degenerative diseases, appar-
ent OA was excluded. However, the preclinical state of
joint disorders within the controls could have affected
the association results. Fourth, because of our marker
selection, we did not fully cover the whole CDH2 gene
when tagging SNPs. This deficiency is one that could be
solved by screening existing genome-wide association
data on OA (2). Since SFs are only 1 candidate cell type
in the joint that is potentially responsible for OA onset
and progression, future studies should expand N-cad-
herin analysis to other cells and their interaction within
the joint.
The exact role of N-cadherin for OA susceptibility
has yet to be defined. Further analyses should be aimed
at the interaction of genetic variants in CDH2 with
known risk factors for OA, such as age, increased
body-mass index, mechanical stress, and microinjuries
of the joint.
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